N M Rao|S N Ghosh - JoVE Visualize

Showing results (131-140 of 143) with videos related to

Pageof 15

Sort By:

AJNR. American Journal of Neuroradiology|November 19, 2021

Reduced Leukoaraiosis, Noncardiac Embolic Stroke Etiology, and Shorter Thrombus Length Indicate Good Leptomeningeal Collateral Flow in Embolic Large-Vessel OcclusionT Hashimoto, T Kunieda, T Honda, et al.

Plos One|February 6, 2014

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumabAhmad A Tarhini, Howard Edington, Lisa H Butterfield, et al.

Melanoma Research|August 22, 2017

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanomaAhmad A Tarhini, Theofanis Floros, Hui-Min Lin, et al.

Gynecologic Oncology Reports|September 14, 2019

Sixteen year-old with leiomyosarcoma in a prior benign myomectomy siteJennifer A Vaz, Payam Katebi Kashi, Saeid Movahedi-Lankarani, et al.

Hepatology (Baltimore, Md.)|September 29, 2006

Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomasJian-Hua Luo, Baoguo Ren, Sergei Keryanov, et al.

Journal for Immunotherapy of Cancer|October 25, 2018

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoireAhmad Tarhini, Yan Lin, Huang Lin, et al.

Cancer Biology & Therapy|February 17, 2006

Increased gene copy number of the transcription factor E2F1 in malignant melanomaMark A Nelson, Steven H Reynolds, Uma N M Rao, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018

E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced MelanomaAhmad A Tarhini, Sandra J Lee, Xiaoxue Li, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 7, 2010

Pharmacodynamic (phase 0) study using etaracizumab in advanced melanomaStergios J Moschos, Cindy A Sander, Wenjun Wang, et al.

Molecular Therapy : the Journal of the American Society of Gene Therapy|October 9, 2014

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityHerbert J Zeh, Stephanie Downs-Canner, J Andrea McCart, et al.

Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:

Pageof 15

AJNR. American Journal of Neuroradiology|November 19, 2021

Reduced Leukoaraiosis, Noncardiac Embolic Stroke Etiology, and Shorter Thrombus Length Indicate Good Leptomeningeal Collateral Flow in Embolic Large-Vessel OcclusionT Hashimoto, T Kunieda, T Honda, et al.

Plos One|February 6, 2014

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumabAhmad A Tarhini, Howard Edington, Lisa H Butterfield, et al.

Melanoma Research|August 22, 2017

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanomaAhmad A Tarhini, Theofanis Floros, Hui-Min Lin, et al.

Gynecologic Oncology Reports|September 14, 2019

Sixteen year-old with leiomyosarcoma in a prior benign myomectomy siteJennifer A Vaz, Payam Katebi Kashi, Saeid Movahedi-Lankarani, et al.

Hepatology (Baltimore, Md.)|September 29, 2006

Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomasJian-Hua Luo, Baoguo Ren, Sergei Keryanov, et al.

Journal for Immunotherapy of Cancer|October 25, 2018

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoireAhmad Tarhini, Yan Lin, Huang Lin, et al.

Cancer Biology & Therapy|February 17, 2006

Increased gene copy number of the transcription factor E2F1 in malignant melanomaMark A Nelson, Steven H Reynolds, Uma N M Rao, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018

E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced MelanomaAhmad A Tarhini, Sandra J Lee, Xiaoxue Li, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 7, 2010

Pharmacodynamic (phase 0) study using etaracizumab in advanced melanomaStergios J Moschos, Cindy A Sander, Wenjun Wang, et al.

Molecular Therapy : the Journal of the American Society of Gene Therapy|October 9, 2014

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityHerbert J Zeh, Stephanie Downs-Canner, J Andrea McCart, et al.

Pageof 15